期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 15, 期 -, 页码 453-462出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S240654
关键词
enfortumab vedotin; bladder cancer; metastasis; urothelial cancer
The therapeutic landscape for advanced and metastatic urothelial carcinoma is evolving, with the recent approval of enfortumab vedotin showing favorable antitumor effectiveness and an acceptable safety profile in heavily pretreated patients.
Nowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据